Telic Inc. has confirmed that its drug, Telcyta showed positive results in an early-stage trial as a combination therapy for non-small cell lung cancer patients. As a result the shares of have gone up by 33 percent in after-market trade.

Telcyta, which is a combination of carboplatin and paclitaxel chemotherapy drugs followed by Telcyta maintenance therapy was well tolerated by the patients, as per the company.

The trial involved 129 patients who were treated with Telcyta in combination with carboplatin and paclitaxel. A total of 100 patients continued to respond at the end of the therapy and were eligible to undergo single agent Telcyta maintenance therapy.

The results are very important for the company since it is pursuing corporate partners to help in the further development of Telcyta which has been in multiple Phase 2 and Phase 3 trials for other cancers including ovarian cancer and non-small cell lung cancer.

However more tests need to be conducted before a potential regulatory submission. Another drug, Telintra, is in the Phase 2 stage of clinical development. It is a small molecule product candidate designed to stimulate the production of blood cells in the bone marrow.

No revenues have been reported by the company in the last three years but it has narrowed its loss since 2006 by bringing down the costs.

Telik is being very vigilant about the costs and for the second quarter the operating costs were very low due to job cuts, reduced research, clinical trial and related expenses and lower stock compensation.